Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem ® is a trademark of Actinogen Medical.
Stockhead on MSN
Biocurious: In a drug-development wasteland, Actinogen zeroes in on an effective Alzheimer’s disease treatment
While Alzheimer's drug developers have spent US$50 billion on suboptimal treatments, Actinogen strives for a breakthrough ...
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and diagnostic assays for patients with Alzheimer's disease (AD) and other ...
The ocean-based carbon removal startup has expanded its partnerships and funding and is eyeing a path to commercial ...
A Reserve Bank tech drama on Tuesday took out almost all file-based payments and delayed PEXA settlements in the latest ...
Condor Energies, Inc. engages in the exploration and development of oil and gas properties. It holds interest on the Poyraz Ridge and Destan in Turkey. The company was founded on October 20, 2006 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results